Since its discovery in the 1990s, “programmed cell death protein 1,” or PD-1, has been regarded as a leading target in cancer treatments. A “checkpoint” receptor that often resides on the surface of ...

Scientists have discovered significant discrepancies in PD-1 between humans and rodents, indicating that common lab models ...

Following a recent trial, doctors at the Christie Hospital are optimistic about the study of HMBD-001 in the treatment of bladder cancer.

Analogic Corp., the Peabody-based maker of medical and airport-security equipment, plans to move its headquarters and ...

By narrowing their research to overweight and obese individuals, Roswell Park researchers found that metformin might offer ...

Immuno-oncology (IO) drugs or cancer therapeutics represent one of the most promising areas of medical innovation in the next ...

The messaging security market grows as online threats rise and demand for stricter rules and regulations increases. David Correa Allied Market Research +1 800-792-5285 email us here Visit us on social ...

While frequent U.S. flyers may recognize optional face-scanning tech like TSA-approved Clear, Russia just rolled out a system ...

Fintel reports that on January 2, 2025, Goldman Sachs downgraded their outlook for Check Point Software Technologies ...

HIF1α identified as key regulator that induces cancer-killing ability of hypoxic T cells, playing a role in ICB resistance.

Check Point Software Technologies Ltd. (NASDAQ:CHKP – Get Free Report) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short ...

Check Point (CHKP – Research Report) received a Hold rating and a $207.00 price target from Goldman Sachs analyst Gabriela Borges yesterday.